ストックスクリーナーアプリを入手
167.93
0.53%
-0.90
アフターアワーズ：
164.50
-3.43
-2.04%
Biogen Inc (BIIB) 最新ニュース
How reliable is Biogen Inc. (IDP) stock dividend growthJuly 2025 Outlook & Fast Entry and Exit Trade Plans - newser.com
Why Biogen Inc. stock is considered a top pick2025 Earnings Surprises & AI Powered Buy and Sell Recommendations - newser.com
Is Biogen Inc. (IDP) stock a buy before earnings results2025 EndofYear Setup & Growth Focused Stock Reports - newser.com
Why Biogen Inc. (IDP) stock benefits from AI revolutionWeekly Trade Recap & AI Powered Market Entry Ideas - newser.com
Biogen to Participate in Upcoming Investor Conferences - Biogen
How analysts rate Biogen Inc. stock todayWeekly Risk Report & Consistent Profit Alerts - newser.com
Does Biogen’s (BIIB) Rare Disease Pipeline Gain Momentum with New Dravet Study Data? - simplywall.st
Biogen’s SWOT analysis: mixed outlook as Alzheimer’s drug gains traction amid stock valuation concerns - Investing.com Nigeria
Biogen Options Trading: A Deep Dive into Market Sentiment - Benzinga
Biogen, Stoke Release Final BUTTERFLY Study Data - Nasdaq
"LEQEMBI(R)" (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease Approved in the United Kingdom - TradingView
Biogen Stock: Is Wall Street Bullish or Bearish? - Barchart.com
Biogen (BIIB) and Stoke Release Results from Dravet Syndrome Stu - GuruFocus
Biogen (BIIB) Reveals Key Findings from Dravet Syndrome Study - GuruFocus
Biogen Says EU Committee Recommends Approval of High Dose Nusinersen Regimen - MarketScreener
Biogen Completes Acquisition of Alcyone Therapeutics - FinSMEs
Stoke Therapeutics and Biogen Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral Impairments - Business Wire
European regulator backs high-dose nusinersen for spinal muscular atrophy By Investing.com - Investing.com Australia
European regulator backs high-dose nusinersen for spinal muscular atrophy - Investing.com
Biogen (BIIB) Advances High Dose Spinal Muscular Atrophy Treatme - GuruFocus
Biogen acquires Alcyone to boost CNS drug delivery - Yahoo Finance
High dose regimen of Nusinersen receives positive CHMP opinion for the treatment of spinal muscular atrophy - MarketScreener
High Dose Regimen of Nusinersen Receives Positive CHMP Opinion for the Treatment of Spinal Muscular Atrophy - Biogen
Why Biogen Inc. (IDP) stock stays on top picksWeekly Trend Recap & AI Driven Price Predictions - newser.com
Chart based exit strategy for Biogen Inc.Portfolio Update Summary & AI Based Buy and Sell Signals - newser.com
Key metrics from Biogen Inc.’s quarterly dataRisk Management & Daily Risk Controlled Trade Plans - newser.com
Will Biogen Inc. (IDP) stock benefit from commodity supercycle2025 Key Lessons & AI Driven Stock Price Forecasts - newser.com
STATE STREET CORP Reduces Stake in Biogen Inc: A Detailed Analys - GuruFocus
Analyzing Biogen Inc. with multi timeframe chartsJuly 2025 Retail & Verified Momentum Watchlists - newser.com
Biogen completes acquisition of Alcyone Therapeutics By Investing.com - Investing.com India
Fund Update: 282,084 BIOGEN (BIIB) shares added to Zurcher Kantonalbank (Zurich Cantonalbank) portfolio - Quiver Quantitative
Biogen completes acquisition of Alcyone Therapeutics - MarketScreener
How Biogen Inc. (IDP) stock behaves in tightening cyclesWeekly Profit Analysis & Fast Entry and Exit Trade Plans - newser.com
Discipline and Rules-Based Execution in BIIB Response - news.stocktradersdaily.com
Biogen stock hits 52-week high at 167.87 USD By Investing.com - Investing.com Canada
Biogen stock hits 52-week high at 167.87 USD - Investing.com India
How to escape a deep drawdown in Biogen Inc.Trade Exit Summary & Stepwise Trade Signal Implementation - newser.com
Biogen (BIIB) Gains UK Approval for LEQEMBI Maintenance Dosing - GuruFocus
'LEQEMBI®” (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Approved in the United Kingdom - The Manila Times
Eisai and Biogen's LEQEMBI® Receives Approval for Once Every Four Weeks IV Maintenance Dosing in the UK - Quiver Quantitative
“LEQEMBI®” (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Approved in the United Kingdom - Biogen
“LEQEMBI®” (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Approved in the United Kingdom - GlobeNewswire Inc.
Biogen at TD Cowen Summit: Strategic Focus on I&I and Kidney Innovation - Investing.com
Biogen (BIIB) Valuation in Focus Following Q3 2025 Results and Key Medical Conference Updates - simplywall.st
Biogen Inc: Time to Ride the Surge? - timothysykes.com
What the Options Market Tells Us About Biogen - Benzinga
Biogen Inc. Stock Outperforms Competitors On Strong Trading Day - 富途牛牛
Shine a Light on Healthcare ETFs Amid National Alzheimer's Awareness Month - Yahoo Finance
Biogen’s Alzheimer’s Bet: Can the EVOKE Trial Redefine the Future of Neurology? - Smartkarma
Institutional scanner results for Biogen Inc.Earnings Risk Report & AI Driven Stock Reports - newser.com
Biogen Inc. Stock Underperforms Tuesday When Compared To Competitors Despite Daily Gains - 富途牛牛
2.19%
0.70%
大文字化:
|
ボリューム (24 時間):